ERBB3 and neoplasm: Indeed, while in early-stage CRC patients, only eighty-six out of 180 (47.8%) tumors showed membranous expression of HER-3, with an HER-3 positive tumor cells mean percentage ± SE of 25.7 ± 3.0 (range, 5 to 97%), conversely in the advanced metastatic CRC setting, all 53 primary tumors showed surface HER-3 expression (100%), with an higher HER-3 positive tumor cells mean percentage of 76.1% ± 3.8 (range, 4 to 100%).